反应 #1178463

ord-ef2f923f02254c399bdc2b69cf422097

反应方程式

CN1CCN(c2ccc3c(c2)sc2nc(-c4ccc(NC(=O)Nc5cc(C(C)(C)C)on5)cc4)cn23)CC1
1-(5-tert-butyl-isoxazol-3-yl)-3-{4-[7-(4-methyl-piperazin-1-yl)-benzo[d]imidazo[2,1-b]thiazol-2-yl]-phenyl}-urea
Nc1nc2ccc(N3CCOCC3)cc2s1
6-morpholin-4-ylbenzothiazol-2-ylamine
CN1CCN(c2ccc3nc(N)sc3c2)CC1
6-(4-methylpiperazin-1-yl)-1,3-benzothiazol-2-amine
CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(N5CCOCC5)ccc34)cc2)no1
1-(5-tert-Butyl-isoxazol-3-yl)-3-[4-(7-morpholin-4-yl-benzo[d]imidazo[2,1-b]thiazol-2-yl)-phenyl]-urea

反应条件

详细条件
See reaction.notes.procedure_details.

实验过程

1-(5-tert-butyl-isoxazol-3-yl)-3-{4-[7-(4-methyl-piperazin-1-yl)-benzo[d]imidazo[2,1-b]thiazol-2-yl]-phenyl}-urea. was prepared in a manner similar to Steps A-D, except that in Step A, 6-morpholin-4-ylbenzothiazol-2-ylamine was substituted with 6-(4-methylpiperazin-1-yl)-1,3-benzothiazol-2-amine. 1H NMR (CDCl3) δ 9.3 (br, 1H), 7.84 (d and s, 3H), 7.59 (br, 1H), 7.56 (d, 2H), 7.49 (d, 1H), 7.20 (d, 1H), 7.05 (dd, 1H), 5.86 (s, 1H), 3.250 (t, 4H), 2.62 (t, 4H), 2.38 (s, 3H), 1.36 (s, 9H). [Compound A7]

来源

DOI: 10.6084/m9.figshare.5104873.v1专利: US08129374B2uspto-grants-2012_03